Abstract：
BACKGROUND: Post-marketing surveillance found montelukast use was associated with an increased risk of depression. However, results of observational studies are inconsistent.
OBJECTIVE: This study aimed to assess whether montelukast exposure is associated with depression and elucidate the possible molecular mechanism.
METHODS: We conducted a cross-sectional study of 9508 adults from the National Health and Nutrition Examination Survey (NHANES) 2007-2016. Multivariable regression was used to evaluate the association between montelukast exposure and depression. Network pharmacology was conducted to identify the mechanisms of montelukast on depression.
RESULTS: Montelukast exposure had a higher prevalence of depression (37.4 %). In a multivariable logistic regression model adjusted for sociodemographic, behavioural, and health characteristics, montelukast exposure was associated with depression (odds ratio [OR]: 1.61; confidence interval [CI]: 1.18-2.19). Network pharmacology was identified 69 key targets of montelukast on depression. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis suggested montelukast mainly works through multiple pathways in endocrine resistance, chemical carcinogenesis-receptor activation, estrogen signaling pathway, etc. LIMITATIONS: Cross-sectional data.
CONCLUSIONS: The study implies a potential positive association between long-term montelukast exposure and depression through multi-faceted mechanisms. It is suggested that attention be given to the possibility of depression in patients undergoing prolonged montelukast therapy.
OBJECTIVE: This study aimed to assess whether montelukast exposure is associated with depression and elucidate the possible molecular mechanism.
METHODS: We conducted a cross-sectional study of 9508 adults from the National Health and Nutrition Examination Survey (NHANES) 2007-2016. Multivariable regression was used to evaluate the association between montelukast exposure and depression. Network pharmacology was conducted to identify the mechanisms of montelukast on depression.
RESULTS: Montelukast exposure had a higher prevalence of depression (37.4 %). In a multivariable logistic regression model adjusted for sociodemographic, behavioural, and health characteristics, montelukast exposure was associated with depression (odds ratio [OR]: 1.61; confidence interval [CI]: 1.18-2.19). Network pharmacology was identified 69 key targets of montelukast on depression. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis suggested montelukast mainly works through multiple pathways in endocrine resistance, chemical carcinogenesis-receptor activation, estrogen signaling pathway, etc. LIMITATIONS: Cross-sectional data.
CONCLUSIONS: The study implies a potential positive association between long-term montelukast exposure and depression through multi-faceted mechanisms. It is suggested that attention be given to the possibility of depression in patients undergoing prolonged montelukast therapy.
摘要：
背景：上市后监测发现使用孟鲁司特与抑郁症风险增加相关。然而,观察性研究的结果不一致.
目的：本研究旨在评估孟鲁司特暴露是否与抑郁症相关，并阐明可能的分子机制。
方法：我们对2007-2016年国家健康与营养调查（NHANES）的9508名成年人进行了横断面研究。多因素回归分析用于评估孟鲁司特暴露与抑郁症之间的关系。进行网络药理学以确定孟鲁司特治疗抑郁症的机制。
结果：孟鲁司特暴露有较高的抑郁症患病率（37.4%）。在经过社会人口统计学调整的多变量逻辑回归模型中，行为，和健康特征，孟鲁司特暴露与抑郁相关(比值比[OR]:1.61;置信区间[CI]:1.18-2.19).网络药理学确定了孟鲁司特治疗抑郁症的69个关键靶点。京都基因和基因组百科全书（KEGG）富集分析表明，孟鲁司特主要通过多种途径在内分泌抗性中起作用，化学致癌-受体激活，雌激素信号通路等。限制：横截面数据。
结论：本研究提示长期孟鲁司特暴露与抑郁症之间存在多方面机制的潜在正相关。建议注意接受长期孟鲁司特治疗的患者患抑郁症的可能性。
目的：本研究旨在评估孟鲁司特暴露是否与抑郁症相关，并阐明可能的分子机制。
方法：我们对2007-2016年国家健康与营养调查（NHANES）的9508名成年人进行了横断面研究。多因素回归分析用于评估孟鲁司特暴露与抑郁症之间的关系。进行网络药理学以确定孟鲁司特治疗抑郁症的机制。
结果：孟鲁司特暴露有较高的抑郁症患病率（37.4%）。在经过社会人口统计学调整的多变量逻辑回归模型中，行为，和健康特征，孟鲁司特暴露与抑郁相关(比值比[OR]:1.61;置信区间[CI]:1.18-2.19).网络药理学确定了孟鲁司特治疗抑郁症的69个关键靶点。京都基因和基因组百科全书（KEGG）富集分析表明，孟鲁司特主要通过多种途径在内分泌抗性中起作用，化学致癌-受体激活，雌激素信号通路等。限制：横截面数据。
结论：本研究提示长期孟鲁司特暴露与抑郁症之间存在多方面机制的潜在正相关。建议注意接受长期孟鲁司特治疗的患者患抑郁症的可能性。
